Overexpression NUFIP1 idiopathic pulmonary fibrosis model
By overexpressing the NUFIP1 gene in lung fibroblasts or lung epithelial cells, and using adeno-associated viral vectors to target the overexpression of NUFIP1 in mouse lung tissues, a idiopathic pulmonary fibrosis model was constructed, which solved the problem that the existing model could not simulate disease microscopy Environmental problems have achieved effective induction of pulmonary fibrosis and drug screening.
Patent Information
- Application Number
- CN202411399770.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-09
- Publication Date
- 2024-11-15
AI Technical Summary
The existing idiopathic pulmonary fibrosis models cannot effectively simulate the microenvironment of the disease, and traditional drug-induced methods cause damage to animals, and there is a lack of effective treatment options.
By overexpressing the NUFIP1 gene in lung fibroblasts or lung epithelial cells, and using adeno-associated viral vectors to target the overexpression of NUFIP1 in mouse lung tissues, constructing idiopathic pulmonary fibrosis cells and animal models to simulate idiopathic pulmonary fibers A microenvironment can avoid damage to animals.
The constructed model is closer to the microenvironment of idiopathic pulmonary fibrosis and can effectively induce pulmonary fibrosis, providing an experimental model closer to human diseases and a new method for screening therapeutic drugs.
Smart Images

Figure CN118956974A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to an idiopathic pulmonary fibrosis model overexpressing NUFIP1, and belongs to the technical field of biomedicine. Background Art
[0002] Fibrosis is formed by the thickening or scarring of connective tissue due to injury, and is characterized by excessive proliferation of fibroblasts and accumulation of extracellular matrix components. This abnormality is common in organs such as the lungs, liver, and kidneys, causing tissue structural damage and severe organ dysfunction. The most common type of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF), which is a chronic fibrotic interstitial pneumonia with unknown pathogenesis and poor prognosis. The disease mainly affects patients over 50 years old, with more men than women. There are about 3 million IPF patients worldwide. Currently, only pirfenidone and nintedanib are available on the market for IPF, which mainly slow down the progression of IPF by delaying the decline of lung function, but their efficacy is limited and their tolerability is poor. The disease burden that IPF imposes on individuals, families, society, and public health resources cannot be underestimated. IFP is a fibroproliferative disease in which chronic damage to alveolar epithelial cells and abnormal tissue repair lead to the formation of fibroblast foci. Fibroblastic foci are mainly composed of fibroblasts and myofibroblasts. Myofibroblasts are the activated form of fibroblasts, which can cause basement membrane disruption, promote epithelial cell apoptosis, and prevent subsequent re-epithelialization. At the same time, they lead to excessive deposition of extracellular matrix, causing pulmonary fibrosis, destruction of lung structure and loss of lung function.
[0003] There is currently no drug that can cure IPF, and building an idealized disease model of idiopathic pulmonary fibrosis (IPF) will help screen candidate drugs and develop new drugs for the treatment of idiopathic pulmonary fibrosis (IPF). Currently, bleomycin or other drugs are usually used to induce the construction of cell and animal pulmonary fibrosis models. There are many inducers used to make models, such as bleomycin, paraquat, high concentrations of oxygen, asbestos, and radiation, which can cause lung damage and eventually lead to pulmonary fibrosis. Bleomycin is the most commonly used.
[0004] The mechanism of bleomycin-induced pulmonary fibrosis is generally believed to be that BLM induces DNA breakage, produces free radicals, induces oxidative stress response, causes cell apoptosis or necrosis, and induces inflammatory response and fibrosis. Because the pathological histological changes are closest to human pulmonary fibrosis, and bleomycin is inexpensive, easy to obtain and has good reproducibility, the bleomycin-induced pulmonary fibrosis animal model has been the most commonly used experimental pulmonary fibrosis model in the past few decades. The routes of administration of bleomycin include lung-specific administration (intratracheal instillation) and systemic administration (intraperitoneal injection, subcutaneous injection and intravenous injection). Using different routes of administration, the cell types initially damaged by bleomycin are different, and each has its own disadvantages. The disadvantage of intratracheal administration is that fibrosis is self-limiting, and the disadvantage of intravenous administration is that it is not suitable for all animals and takes a long time to form fibrosis; the disadvantage of intraperitoneal injection is that multiple doses are required; the disadvantage of subcutaneous injection is that daily injection or micro-osmotic pump administration is required. The most important thing is that the microenvironment of idiopathic pulmonary fibrosis cannot be well simulated by drug induction. Patent CN113906132A also reports an animal model of idiopathic pulmonary fibrosis, its construction method and use. The method for constructing the animal model of idiopathic pulmonary fibrosis involves performing a lung resection (PNX) on the animal, which causes great damage to the animal. Summary of the invention
[0005] The purpose of the present invention is: to address the deficiencies of the prior art, the present invention provides an idiopathic pulmonary fibrosis model by overexpressing NUFIP1, including an IPF cell model and an animal model. The present invention can successfully induce the activation of lung fibroblasts and construct a fibroblast fibrosis model by overexpressing the NUFIP1 gene at the level of lung fibroblasts or lung epithelial cells; at the animal level, adeno-associated virus is used as a vector to target overexpression of NUFIP1 in mouse lung tissue, which can successfully induce the formation of pulmonary fibrosis in mouse lung tissue.
[0006] In order to achieve the above-mentioned object, the present invention provides a method for constructing an idiopathic pulmonary fibrosis cell model, comprising: transfecting lung fibroblasts or lung epithelial cells with a lentivirus carrying the target gene NUFIP1, and screening to obtain lung fibroblasts or lung epithelial cells overexpressing NUFIP1, that is, an idiopathic pulmonary fibrosis cell model; the idiopathic pulmonary fibrosis cell model has increased expression of NUFIP1, col1a1 and α-SMA.
[0007] In some embodiments of the present invention, the target gene NUFIP1 is a human or animal NUFIP1 gene.
[0008] In some embodiments of the present invention, the lung fibroblasts or lung epithelial cells are from humans or animals.
[0009] In some embodiments of the invention, the animal is a mouse.
[0010] In some embodiments of the present invention, the construction method specifically comprises the following steps:
[0011] Step 1: Clone the target gene NUFIP1 into the pSLenti-EF1-EGFP-P2A-Puro-CMV-MCS-3xFLAG-WPRE vector after restriction digestion to obtain the NUFIP1 overexpression recombinant lentiviral vector;
[0012] Step 2: The virus vector assembled in step 1 is transformed into E. coli Stbl3 competent cells; the transformants are screened by colony PCR, the positive clones are sent for sequencing, and the positive clones are determined by sequence comparison; the positive clones are amplified and the plasmids are extracted;
[0013] Step 3: The plasmid extracted in step 2 is combined with the virus packaging auxiliary plasmids pSPAX2 and pMD2G to form a three-plasmid lentiviral system and co-transfected into 293T cells for virus packaging to obtain virus liquid;
[0014] Step 4: Infect lung fibroblasts or lung epithelial cells with the virus solution obtained in step 3, and screen and obtain lung fibroblasts or lung epithelial cells overexpressing NUFIP1, which is an idiopathic pulmonary fibrosis cell model.
[0015] In some embodiments of the present invention, the sequence of the target gene NUFIP1 is shown as SEQ ID NO:1.
[0016] In some embodiments of the present invention, the target gene is NUFIP1 carrying a 3xflag tag, and the sequence is shown in SEQ ID NO:3.
[0017] The present invention also provides a method for constructing an animal model of idiopathic pulmonary fibrosis, comprising: preparing an adeno-associated virus carrying overexpressed NUFIP1; transfecting the adeno-associated virus overexpressing NUFIP1 into mouse lung tissue by tail vein injection or tracheal instillation, wherein the adeno-associated virus overexpressing NUFIP1 comprises a target gene as shown in SEQ ID NO: 4 or SEQ ID NO: 5. HE and Masson staining results of mouse lung tissue indicate the formation of pulmonary fibrosis.
[0018] In some embodiments of the present invention, the method for constructing an idiopathic pulmonary fibrosis animal model specifically comprises the following steps:
[0019] Step 1: Clone the mouse NUFIP1 gene into the pcAAV-CMV-GdGreen-WPRE vector after restriction digestion to obtain the NUFIP1 overexpression recombinant adeno-associated virus vector;
[0020] Step 2: The recombinant adeno-associated virus vector assembled in step 1 is transformed into E. coli Stbl3 competent cells; the transformants are screened by colony PCR, the positive clones are sent for sequencing, and the positive clones are determined by sequence comparison; the positive clones are amplified and the plasmids are extracted;
[0021] Step 3: The plasmid extracted in step 2 is combined with pHelper plasmid and AAV plasmid to co-transfect AAV-293 cells for virus packaging to obtain AAV virus liquid;
[0022] Step 4: Infect lung fibroblasts or lung epithelial cells with the virus solution obtained in step 3, and screen and obtain lung fibroblasts or lung epithelial cells overexpressing NUFIP1, which is an idiopathic pulmonary fibrosis cell model.
[0023] In some embodiments of the present invention, the AAV plasmid in step 2 is an AAV2 and / or AAV6 plasmid.
[0024] The present invention also provides the use of the cell model constructed by the above construction method in studying idiopathic pulmonary fibrosis and / or in screening drugs for treating idiopathic pulmonary fibrosis.
[0025] The present invention also provides the use of the animal model constructed by the above construction method in studying idiopathic pulmonary fibrosis and / or in screening drugs for treating idiopathic pulmonary fibrosis.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] Compared with the traditional cell and animal pulmonary fibrosis models induced by bleomycin or other drugs, the idiopathic pulmonary fibrosis cell model or animal model overexpressing NUFIP1 constructed by the present invention is closer to the microenvironment of idiopathic pulmonary fibrosis, and constructs an in vivo and in vitro IPF model at the gene level; and there is no need to perform lung resection on the animals, and no damage to the animals is caused. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 Construct a flow chart for the model of the present invention.
[0029] Figure 2 This is a diagram showing the effect of RT-PCR identification of NUFIP1 overexpression and fibrosis in lung fibroblasts.
[0030] Figure 3 This is a diagram showing Western-blot identification of the effect of NUFIP1 overexpression and fibrosis in lung fibroblasts.
[0031] Figure 4This is a diagram showing the effect of RT-PCR identifying NUFIP1 overexpression in mouse lung tissue and causing pulmonary fibrosis.
[0032] Figure 5 This is a diagram showing the effect of Western-blot identification of NUFIP1 overexpression in mouse lung tissue and causing pulmonary fibrosis.
[0033] Figure 6 HE and Masson staining identified the effect of NUFIP1 overexpression in mouse lung tissue and causing pulmonary fibrosis.
[0034] p < 0.05 was considered statistically significant; in the above figures, ns represents p > 0.05, * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and **** represents p < 0.0001. DETAILED DESCRIPTION
[0035] In order to make the present invention more clearly understood, preferred embodiments are described in detail below with reference to the accompanying drawings.
[0036] The experimental methods in the following examples without specifying specific conditions were performed according to conventional methods and conditions, or selected according to the product instructions; the cells, materials, reagents, etc. used were all conventional commercially available products unless otherwise specified.
[0037] Example 1
[0038] Construction of NUFIP1 idiopathic pulmonary fibrosis cell model:
[0039] 1. Design and synthesize NUFIP1 double-stranded DNA fragment carrying 3xflag tag
[0040]
[0041] 2) To realize that the protein encoded by the NUFIP1 gene carries a 3xflag tag, a 3xflag sequence (SEQ ID NO: 2) was added before the stop codon "TAG" of the NUFIP1 protein coding region sequence: gactacaaggatgacgatgacaaggattacaaagacgacgatgataaggactataaggatgatgacgacaaa;
[0042] The NUFIP1 DNA double-stranded fragment sequence carrying the 3xflag tag (underlined) was obtained (SEQ ID NO: 3):
[0043] atggctgagccgactagtgatttcgagactcctatcgggtggcatgcgtctcccgagctgactcccacgttagggcccctga
[0044] gcgacactgccccgccgcgggacagctggatgttctgggcaatgctgccgccaccgccaccaccacttacgtcctcgctt
[0045] cccgcagccgggtcaaagccttcctctgagtcgcagccccccatggaggcccagtctctccccggggctccgcccccctt
[0046] cgacgcccagattcttcccggggcgcaaccccccttcgacgcccagtctccccttgattctcagcctcaacccagcggcca
[0047] gccttggaatttccatgcttccacatcgtggtattggagacagtcttctgataggtttcctcggcatcagaagtccttcaaccct
[0048] gcagttaaaaattcttattatccacgaaagtatgatgcaaaattcacagacttcagcttacctcccagtagaaaacagaaaaaa
[0049] aagaaaagaaaggaaccagtttttcactttttttgtgatacctgtgatcgtggttttaaaaatcaagaaaagtatgacaaacaca
[0050] tgtctgaacatacaaaatgccctgaattagattgctcttttactgcacacgagaagattgtccagttccattggagaaatatgca
[0051] tgctcctggcatgaagaagatcaagttagacactccagaggaaattgcacggtggagggaagaaagaaggaaaaactat
[0052] ccaactctggccaatattgaaaggaagaagaagttaaaacttgaaaaggagaagagaggagcagtattgacaacaacaca
[0053] atatggcaagatgaaggggatgtccagacattcacaaatggcaaagatcagaagtcctggcaagaatcacaaatggaaaa
[0054] acgacaattctagacagagagcagtcactggatcaggcagtcacttgtgtgatttgaagctagaaggtccaccggaggcaa
[0055] atgcagatcctcttggtgttttgataaacagtgattctgagtctgataaggaggagaaaccacaacattctgtgatacccaagg
[0056] aagtgacaccagccctatgctcactaatgagtagctatggcagtctttcagggtcagagagtgagccagaagaaactccca
[0057] tcaagactgaagcagacgttttggcagaaaaccaggttcttgatagcagtgctcctaagagtccaagtcaagatgttaaagc
[0058] aactgttagaaatttttcagaagccaagagtgagaaccgaaagaaaagctttgaaaaaacaaaccctaagaggaaaaaag
[0059] attatcacaactatcaaacgttatattcgaaccaagaacacaccatccatatctctcttggaaatgcttctagctccggacattcgac
[0060] atgaaagaaatgtgattttgcagtgtgttcggtacatcatcaaaaaagacttttttggactggatactaattctgcgaaaagtaa
[0061] agatgta gactacaaggatgacgatgacaaggattacaaagacgacgatgataaggactataaggatg atgacgacaaa tag.
[0062] Shanghai Heyuan Biotechnology Co., Ltd. was commissioned to synthesize the above-mentioned NUFIP1 DNA double-stranded fragment sequence carrying the 3xflag tag.
[0063] 2. Construction of NUFIP1 overexpression lentiviral vector carrying 3x flag tag
[0064] 1) Vector digestion and fragment ligation
[0065] According to the reaction system of 1μl vector DNA (1μg / μl), 4μl 10*buffer, 33.5μl ddH2O, and 1.5μI EcoRI, react in a 37℃ water bath for 1-2h. pSLenti-EF1-EGFP-P2A-Puro-CMV-MCS-3xFLAG-WPRE was digested, and agarose gel electrophoresis was performed after the digestion was completed to recover the target fragment. TM (Seamless Cloning Kit) One-step cloning: The NUFIP1 DNA double-stranded target fragment carrying the 3xflag tag was connected to the pSLenti-EF1-EGFP-P2A-Puro-CMV-MCS-3xFLAG-WPRE vector after restriction digestion to obtain the NUFIP1 overexpression recombinant lentiviral vector pSLenti-EF1-EGFP-P2A-Puro-CMV-NUFIP1-3xFLAG-WPRE.
[0066] 2) Transform the viral vector assembled in step 1 into E. coli Stbl3 competent cells;
[0067] 3) Screen the transformants using colony PCR, send the positive clones for sequencing, and confirm the positive clones by sequence comparison;
[0068] 4) Prepare a large amount of recombinant lentiviral vector pSLenti-EF1-EGFP-P2A-Puro-CMV-NUFIP1-3xFLAG-WPRE plasmid and control pSLenti-EF1-EGFP-P2A-Puro-CMV-MCS-3xFLAG-WPRE plasmid by amplifying bacterial solution and extracting with a plasmid extraction kit;
[0069] 5) Preparation of virus concentrate
[0070] The NUFIP1 overexpression recombinant lentiviral vector pSLenti-EF1-EGFP-P2A-Puro-CMV-NUFIP1-3xFLAG-WPRE plasmid / pSLenti-EF1-EGFP-P2A-Puro-CMV-MCS-3xFLAG-WPRE empty vector plasmid was co-transfected into 293T cells with the virus packaging helper plasmids pSPAX2 and pMD2G (Heyuan Biotechnology (Shanghai) Co., Ltd.) according to the instructions of OproTF transfection reagent (Heyuan Biotechnology (Shanghai) Co., Ltd.), and the cell culture fluid was collected after 48 hours and 72 hours, and the high-titer virus fluid, i.e., the NUFIP1 overexpression / overexpression control virus fluid, was obtained by ultracentrifugation and stored in a -80°C refrigerator.
[0071] 3. Transfection of lung fibroblasts (lung epithelial cells can also be used)
[0072] Add 20 μl of NUFIP1 overexpression / overexpression control virus concentrate to lung fibroblasts with a confluence rate of 70-80%; replace with fresh complete culture medium after 24 hours; use neomycin for positive selection and amplification culture after 48 hours to obtain lung fibroblasts overexpressing NUFIP1.
[0073] 4. Result identification
[0074] RT-PCR, western-blot and immunofluorescence were used to verify that lung fibroblasts overexpressed NUFIP1. Overexpression of NUFIP1 in lung fibroblasts caused activation of lung fibroblasts, and the expression of col1a1 and α-SMA increased. The results are as follows Figure 2 and Figure 3 shown.
[0075] Example 2
[0076] Construction of NUFIP1 idiopathic pulmonary fibrosis animal model:
[0077] 1. Design and synthesize a double-stranded DNA fragment of Nufip1 carrying a 3xflag tag
[0078] 1) By searching the NCBI GenBank database (www.ncbi.nlm.nih.gov / gene) for the transcript NM_013745.5 of the mouse NUFIP1 gene (mouse NUFIP1 is denoted as Nufip1, GeneID: 27275), the sequence of the Nufip1 protein coding region (SEQ ID NO: 4) is as follows:
[0079] Atggctgaaccggcacccgccgtgtggccttcggccccggatctgactcccgcgcccgggactccgagcgaagctgcg
[0080] ccgccgcgggacaactgggtgtactgggccatgctgccgccgccaccacctcctctgtcgtccccagtggcgggctcgg
[0081] agcagagccggaagggacagcctcacgtgctgccccagcctccctccggagcgcttccaccgttcgatgctcagattctt
[0082] cccgcggcgcagcctcctttcgatgcccaggctccgcccgatgctcaatctcagttcagcggccagcaggcctggaatttg
[0083] caagcctccacgccttggtactggggattgtctcctaatggtttttccacgtaccacacgtcttaccaatctccggttacacatt
[0084] cttattttccacgatcacatgatgcaaaattcaatttgcctcaaaacagaaaacagaaaacgaagaaaagaaaggaaccggt
[0085] tttccattttttctgtgatacctgtgatcgtggctttaaaaatcaagaaaagtatgacacacacatgtctgaacatacaaaatgcc
[0086] ctgaagtgattgctcctttagtgcacatgaagaattgtccagttccattggagaaatatgcatgctcctggtatgaagaaga
[0087] tcaagctagacactccagaggagattgcaagatggagggaagagaacgaaaaaactacccaactctggccaatattga
[0088] aaagaagaaaaagttacaactggaaaaggcaaagagaggaagagtgttgacaaccacacagtatggcaaaatgaaggg
[0089] catgtccagacattcacagatggcaaagatcagaagtcctggtaaacatcataaatgggaagaggtggggctaggcaga
[0090] gagcagtcgttggactaggaaatcatgccagagattcgaagcctgaagttccatccaaggctaatgtggacccttaggtg
[0091] ctttgatccacagcgactctgagtctgataaggaagaagaagcgcaaaggactgtagtgcccaaggaagtgacaccagcc
[0092] ttgtgttcgctgatgagcagctacggcgatgtctcggggtcagacagtgagccagaagaagctcccatcaagaactgaagc
[0093] agaagttctggcagaaaaccatgttcttcatagcagtcctcccaagagtccaaaacaaaatgttcaaacaactggtagaaca
[0094] gtctcaagatccaagtgggagaaccagagaacggactcagaaagataagccttaagcggaaaagagccactgtcacc
[0095] cattatttgaaccaagaacacatcacccatatctcctggaaatgcttctagctccagatattcgacatgaaagaaatgtgattttgcagtgtgttcgatatatcatcaaaaaagacttttttggacttaatactgattctgtgaaaactgaagaagtgtag;
[0096] 2) To achieve that the protein encoded by the Nufip1 gene carries a 3xflag tag, a 3xflag sequence (SEQ ID NO: 2) was added before the stop codon "TAG" of the Nufip1 protein coding region sequence: gactacaaggatgacgatgacaaggattacaaagacgacgatgataaggactataaggatgatgacgacaaa;
[0097] The Nufip1 DNA double-stranded fragment sequence carrying the 3xflag tag (underlined) was obtained (Nufip1-3xFLAG, SEQ ID NO: 5):
[0098] gactacaaggatgacgatgacaaggattacaaagacgacgatgataaggactataaggat gatgacgacaaa tag.
[0099] 4) and Yuan Biotech to synthesize the above-mentioned Nufip1 DNA double-stranded fragment sequence carrying the 3xflag tag.
[0100] 2. Construction of NUFIP1 overexpression adeno-associated virus vector
[0101] 1) Vector digestion and fragment ligation
[0102] According to the reaction system of 1μl vector DNA (1μg / μl), 4μl 10*buffer, 33.5μl ddH2O, and 1.5μI EcoRI, the reaction was carried out in a 37°C water bath for 1-2h, and the pcAAV-CMV-GdGreen-WPRE was digested by enzyme, and agarose gel electrophoresis was performed after the digestion was completed, and the target fragment was recovered by gel. The Nufip1 target gene was obtained by PCR amplification, and then assembled with the adeno-associated virus vector pcAAV-CMV-GdGreen-WPRE by homologous recombination with the homologous recombinase Exnase to obtain the Nufip1 overexpression recombinant adeno-associated virus vector pcAAV-CMV-Nufip1-3xFLAG-P2A-GdGreen-WPRE.
[0103] 2) Transform the viral vector assembled in step 1 into E. coli Stbl3 competent cells;
[0104] 3) Screen the transformants using colony PCR, send the positive clones for sequencing, and confirm the positive clones by sequence comparison;
[0105] 4) Prepare a large amount of recombinant lentiviral vector pcAAV-CMV-Nufip1-3xFLAG-P2A-GdGreen-WPRE plasmid and control pcAAV-CMV-GdGreen-WPRE plasmid by amplifying the bacterial solution using a plasmid extraction kit;
[0106] 5) The screened and identified NUFIP1 overexpression recombinant viral vector pcAAV-CMV-Nufip1-3xFLAG-P2A-GdGreen-WPRE / pcAAV-CMV-GdGreen-WPRE empty vector was co-transfected with pHelper plasmid, AAV2 and AAV6 plasmids (Heyuan Biotechnology (Shanghai) Co., Ltd.) to AAV-293 cells according to the instructions of OproTF transfection reagent (Heyuan Biotechnology (Shanghai) Co., Ltd.) to complete the virus packaging. The viral supernatant and cells were collected after 72 hours, the cells were lysed, the virus was concentrated and purified by density gradient centrifugation to obtain high-titer Nufip1 overexpression / overexpression control adeno-associated virus solution, which was packaged and stored in a -80°C refrigerator.
[0107] 3. The above-mentioned adeno-associated virus carrying overexpressed Nufip1 was transfected into the mouse lung tissue by tail vein injection or tracheal instillation.
[0108] 4. Result identification
[0109] After AAV-Nufip1 was transfected into mouse lung tissue, NUFIP1 was overexpressed in mouse lung tissue. After RT-PCR and western-blot verification, the results showed that NUFIP1 was successfully overexpressed in mouse lung tissue; NUFIP1 was successfully overexpressed in mouse lung tissue and caused fibrosis in mouse lung tissue. The expression of col1a1 and α-SMA in mouse lung tissue increased. Figure 4 and Figure 5 shown.
[0110] After AAV-Nufip1 was transfected into mouse lung tissue, NUFIP1 was overexpressed in mouse lung tissue and fibrosis of mouse lung tissue was induced. HE and Masson staining results of mouse lung tissue indicated the formation of pulmonary fibrosis. Figure 6 shown.
[0111] The above description is only a preferred embodiment of the present invention and is not any formal or substantial limitation of the present invention. It should be pointed out that a person skilled in the art can make several improvements and supplements without departing from the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention.
Claims
1. A method for constructing a cell model of idiopathic pulmonary fibrosis, characterized in that: include: The lentivirus carrying the target gene NUFIP1 is transfected into lung fibroblasts or lung epithelial cells, and lung fibroblasts or lung epithelial cells overexpressing NUFIP1 are screened to obtain an idiopathic pulmonary fibrosis cell model; the idiopathic pulmonary fibrosis cell model has increased expression of NUFIP1, col1a1 and α-SMA.
2. The construction method according to claim 1, characterized in that: The target gene NUFIP1 is a human or animal NUFIP1 gene; accordingly, the lung fibroblasts or lung epithelial cells are from humans or animals.
3. The construction method according to claim 1, characterized in that: The construction method specifically comprises the following steps: Step 1: Clone the target gene NUFIP1 into the pSLenti-EF1-EGFP-P2A-Puro-CMV-MCS-3xFLAG-WPRE vector after restriction digestion to obtain the NUFIP1 overexpression recombinant lentiviral vector; Step 2: The virus vector assembled in step 1 is transformed into E. coli Stbl3 competent cells; the transformants are screened by colony PCR, the positive clones are sent for sequencing, and the positive clones are determined by sequence comparison; the positive clones are amplified and the plasmids are extracted; Step 3: The plasmid extracted in step 2 is combined with the virus packaging auxiliary plasmids pSPAX2 and pMD2G to form a three-plasmid lentiviral system and co-transfected into 293T cells for virus packaging to obtain virus liquid; Step 4: Infect lung fibroblasts or lung epithelial cells with the virus solution obtained in step 3, and screen and obtain lung fibroblasts or lung epithelial cells overexpressing NUFIP1, which is an idiopathic pulmonary fibrosis cell model.
4. The construction method according to claim 3, characterized in that: The sequence of the target gene NUFIP1 is shown as SEQ ID NO:
1.
5. The construction method according to claim 3, characterized in that: The target gene is NUFIP1 carrying a 3xflag tag, and the sequence is shown in SEQ ID NO:
3.
6. A method for constructing an animal model of idiopathic pulmonary fibrosis, characterized in that: include: An adeno-associated virus carrying overexpressed NUFIP1 is prepared; the adeno-associated virus overexpressing NUFIP1 is transfected into mouse lung tissue by tail vein injection or tracheal instillation to obtain an idiopathic pulmonary fibrosis animal model; the adeno-associated virus overexpressing NUFIP1 comprises a target gene as shown in SEQ ID NO: 4 or SEQ ID NO:
5.
7. The construction method according to claim 6, characterized in that: The construction method specifically comprises the following steps: Step 1: Clone the mouse NUFIP1 gene into the pcAAV-CMV-GdGreen-WPRE vector after restriction digestion to obtain the NUFIP1 overexpression recombinant adeno-associated virus vector; Step 2: The recombinant adeno-associated virus vector assembled in step 1 is transformed into E. coli Stbl3 competent cells; the transformants are screened by colony PCR, the positive clones are sent for sequencing, and the positive clones are determined by sequence comparison; the positive clones are amplified and the plasmids are extracted; Step 3: The plasmid extracted in step 2 is combined with pHelper plasmid and AAV plasmid to co-transfect AAV-293 cells for virus packaging to obtain AAV virus liquid; Step 4: Infect lung fibroblasts or lung epithelial cells with the virus solution obtained in step 3, and screen and obtain lung fibroblasts or lung epithelial cells overexpressing NUFIP1, which is an idiopathic pulmonary fibrosis cell model.
8. The construction method according to claim 6, characterized in that: The AAV plasmid in step 2 is AAV2 and / or AAV6 plasmid.
9. Use of the cell model constructed by the construction method according to any one of claims 1 to 5 in studying idiopathic pulmonary fibrosis and / or in screening drugs for treating idiopathic pulmonary fibrosis.
10. Use of the animal model constructed by the construction method according to any one of claims 6 to 8 in studying idiopathic pulmonary fibrosis and / or in screening drugs for treating idiopathic pulmonary fibrosis.
